- Home
- SNSE vs INDP Comparison
SNSE vs INDP Comparison
Compare SNSE & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- INDP
- Stock Information
- Founded
- SNSE 2005
- INDP 2000
- Country
- SNSE United States
- INDP United States
- Employees
- SNSE N/A
- INDP N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- SNSE Health Care
- INDP Health Care
- Exchange
- SNSE Nasdaq
- INDP Nasdaq
- Market Cap
- SNSE 12.5M
- INDP 10.2M
- IPO Year
- SNSE 2021
- INDP N/A
- Fundamental
- Price
- SNSE $0.53
- INDP $0.84
- Analyst Decision
- SNSE Strong Buy
- INDP Strong Buy
- Analyst Count
- SNSE 3
- INDP 2
- Target Price
- SNSE $4.33
- INDP $8.50
- AVG Volume (30 Days)
- SNSE 769.5K
- INDP 25.3K
- Earning Date
- SNSE 02-26-2025
- INDP 03-12-2025
- Dividend Yield
- SNSE N/A
- INDP N/A
- EPS Growth
- SNSE N/A
- INDP N/A
- EPS
- SNSE N/A
- INDP N/A
- Revenue
- SNSE N/A
- INDP N/A
- Revenue This Year
- SNSE N/A
- INDP N/A
- Revenue Next Year
- SNSE N/A
- INDP N/A
- P/E Ratio
- SNSE N/A
- INDP N/A
- Revenue Growth
- SNSE N/A
- INDP N/A
- 52 Week Low
- SNSE $0.38
- INDP $0.81
- 52 Week High
- SNSE $1.94
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- SNSE 56.84
- INDP 39.07
- Support Level
- SNSE $0.47
- INDP $0.86
- Resistance Level
- SNSE $0.55
- INDP $1.06
- Average True Range (ATR)
- SNSE 0.05
- INDP 0.08
- MACD
- SNSE 0.00
- INDP 0.00
- Stochastic Oscillator
- SNSE 65.98
- INDP 12.80
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.